Personalized medicine, where prevention, diagnosis, and/or
treatment of disease is tailored to a particular individual, is
becoming more and more prevalent as scientists uncover new
connections between biomarkers and illnesses. However, developments
in the Canadian Intellectual Property Office (CIPO) over the last
several years have made it increasingly difficult to patent
technologies related to molecular diagnostics. This article reviews
the current position of CIPO with respect to diagnostic patent
claims and looks at recent developments in the United
States.
At issue are patent claims directed to methods of diagnosing a
particular disease in a subject where the inventors have identified
a new association between a known biomarker and the disease. Such
claims are now routinely objected to by Canadian patent examiners
as being directed to non-patentable subject matter, despite meeting
the other requirements for patentability, namely novelty,
non-obviousness and